相关实验视频
Updated: Oct 7, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
在冠状动脉支架干预中使用eptifibatide阻断血小板糖蛋白IIb/IIIa整体蛋白:ESPRIT试验:一种随机对照试验
J C O'Shea1, G E Hafley, S Greenberg
1Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705, USA.
JAMA
|May 23, 2001
概括
在冠状动脉支架植入期间给予的eptifibatide治疗显著降低了6个月的死亡或心脏病发作风险. 这些早期观察到的好处在6个月的随访期内持续存在.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 该ESPRIT试验证明了eptifibatide在48小时30天内在冠状动脉支架植入后减少缺血并发症的有效性.
- 这项研究旨在评估这些益处的长期持续性.
研究的目的:
- 确定eptifibatide治疗的积极影响是否延伸到冠状动脉支架植入后的6个月.
- 评估eptifibatide对缺血事件和死亡率的持续影响.
主要方法:
- 一项随机,双盲,安慰剂对照试验的后续分析,该试验涉及2064名接受非紧急皮肤冠状动脉干预与支架植入的患者.
- 患者接受了eptifibatide或安慰剂,死亡率,心肌梗塞 (MI) 和目标血管再血管化的复合率在6个月后被评估.
主要成果:
- 治疗eptifibatide导致6个月的死亡或MI的复合率显著降低 (7.5%对11.5%,HR 0.63,P=.002).
- 在eptifibatide组中,死亡,心脏病发作或目标血管再血管化的复合率也较低 (14.2%对18.3%,HR 0.75,P=.008).
- 观察到的好处主要是在早期积累的,并保持在6个月的随访期间.
结论:
- 在冠状动脉支架植入期间进行的辅助eptifibatide治疗提供长达6个月的持续临床益处.
- 这些发现支持在接受非紧急冠状动脉支架的患者中继续使用eptifibatide,以减少长期缺血并发症.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...